Journal
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume 39, Issue 9, Pages 1739-1746Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.119.312461
Keywords
atherosclerosis; cardiac arrhythmias; cardiomyopathy; methamphetamine; pulmonary hypertension; substance-related disorders; vasoconstriction
Categories
Funding
- Institutional Development Award from the National Institutes of General Medical Sciences of the National Institutes of Health (NIH) [P20GM121307]
- NIH [R01 HL098435, HL133497, HL141155, HL131844, HL122354, HL145753]
Ask authors/readers for more resources
While the opioid epidemic has garnered significant attention, the use of methamphetamines is growing worldwide independent of wealth or region. Following overdose and accidents, the leading cause of death in methamphetamine users is cardiovascular disease, because of significant effects of methamphetamine on vasoconstriction, pulmonary hypertension, atherosclerotic plaque formation, cardiac arrhythmias, and cardiomyopathy. In this review, we examine the current literature on methamphetamine-induced changes in cardiovascular health, discuss the potential mechanisms regulating these varied effects, and highlight our deficiencies in understanding how to treat methamphetamine-associated cardiovascular dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available